Cable Hill Partners’s Alder Biopharmaceuticals ALDR Stock Holding History

Cable Hill Partners’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13	Closed	–	–	1000
2017 Q4	$0	Sell	13 -174	-93%	-$1.94K	﹤0.01%	1060
2017 Q3	$2K	Sell	187 -5	-3%	-$52	﹤0.01%	952
2017 Q2	$2K	Sell	192 -1	-0.5%	-$18	﹤0.01%	702
2017 Q1	$4K	Buy	193 +168	+672%	+$3.72K	﹤0.01%	606
2016 Q4	$1K	Sell	25 -181	-88%	-$4.71K	﹤0.01%	711
2016 Q3	$6K	Sell	206 -11	-5%	-$335	﹤0.01%	542
2016 Q2	$6K	Hold	217	–	–	﹤0.01%	487
2016 Q1	$6K	Sell	217 -6	-3%	-$139	﹤0.01%	463
2015 Q4	$8K	Hold	223	–	–	0.01%	402
2015 Q3	$8K	Sell	223 -4	-2%	-$170	0.01%	423
2015 Q2	$12K	Hold	227	–	–	0.01%	410
2015 Q1	$6K	Buy	+227	New	+$6.23K	﹤0.01%	546

Other funds holding ALDR

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cable Hill Partners's ALDR Position: Q1 2018 in Review

Cable Hill Partners sold out of Alder Biopharmaceuticals (ALDR) in Q1 2018, closing a stake of 13 shares.

Cable Hill Partners first reported a position in ALDR in Q1 2015 and held it in 12 quarters. The position peaked at $12K in Q2 2015. 135 funds tracked by Wall St. Rank hold ALDR as of Q1 2018.

Cable Hill Partners reported no remaining Alder Biopharmaceuticals position as of Q1 2018 after selling out during the quarter.
Cable Hill Partners sold 13 Alder Biopharmaceuticals shares in Q1 2018.
Cable Hill Partners first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 12 quarters.
Cable Hill Partners's Alder Biopharmaceuticals position peaked at $12K in Q2 2015.
135 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.